Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: Preliminary findings

Journal of NeuroVirology

Volumn 17, Issue 3, 2011, Pages 239-247

  Gupta, Saurabh ^a   Bousman, Chad A ^b   Chana, Gursharan ^b   Cherner, Mariana ^a   Heaton, Robert K ^a   Deutsch, Reena ^a   Ellis, Ronald J ^c   Grant, Igor ^a   Everall, Ian P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cognitive impairment; Dopamine D3 receptor; HIV; Methamphetamine; SNP

Indexed keywords

DOPAMINE 3 RECEPTOR; METHAMPHETAMINE;

ADULT; ARTICLE; BINDING AFFINITY; COCHRAN ARMITAGE TEST; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DEPENDENCE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR BINDING; RETROSPECTIVE STUDY; SCREENING TEST; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; AMPHETAMINE-RELATED DISORDERS; COGNITION DISORDERS; DOPAMINE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; MALE; METHAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D3; RETROSPECTIVE STUDIES; RISK FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79959952132     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-011-0028-3     Document Type: Article

References (31)

1. Armitage P (1955) Tests for linear trends in proportions and frequencies. Biometrics 11:375-386
2. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561-71
3. Bousman CA, Cherner M, Atkinson JH, Heaton RK, Grant I, Everall IP, HNRC Group (2010) COMT Val158Met polymorphism, executive dysfunction, and sexual risk behavior in the context of HIV infection and methamphetamine dependence. Interdiscip Perspect Infect Dis 2010:1-9. PMCID: PMC2804107
4. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I et al (2004) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26(3):307-319. doi:10.1080/13803390490510031 (Pubitemid 39277061)
5. Cheng WS, Garfein RS, Semple SJ, Strathdee SA, Zians JK, Patterson TL (2010) Increased drug use and STI risk with injection drug use among HIV-seronegative heterosexual methamphetamine users. J Psychoactive Drugs 42(1):11-18
6. Cherner M, Masliah E, Ellis RJ, Marcotte TD, Moore DJ, Grant I et al (2002) Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 59(10):1563-1567 (Pubitemid 35387063)
7. Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Grant I (2003) Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 188(12):1820-1826. doi: JID30762[pii]10.1086/379894 (Pubitemid 38064866)
8. Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, Berman JW (2006) CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV) - infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci 26(4):1098-1106. doi: 10.1523/JNEUROSCI.3863-05.2006 (Pubitemid 43237041)
9. Flierl MA, Rittirsch D, Huber-Lang M, Sarma JV, Ward PA (2008) Catecholamines-crafty weapons in the inflammatory arsenal of immune/inflammatory cells or opening Pandora's box? Mol Med 14(3-4):195-204 (Pubitemid 351481850)
10. Gaskill PJ, Calderon TM, Luers AJ, Eugenin EA, Javitch JA, Berman JW (2009) Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse. Am J Pathol 175(3):1148-1159. doi:10.2353/ajpath.2009.081067
11. Heaton RK, Grant I, Butters N, White DA, Kirson D, Atkinson JH et al (1995) The HNRC 500-neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1(3):231-251
12. Heaton RK, Clifford D, Franklin D, Woods SP, Ake C, Vaida F et al (2010) HIV-associated neurocognitive disorders persist in the era of combination antiretroviral therapy: CHARTER Study. Neurology 75:2087-2096
13. Langford D, Marquie-Beck J, de Ameida S, Lazzaretto D, Letendre S, Grant I et al (2006) Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J Neurovirol 12:100-107 (Pubitemid 44574601)
14. Liang H, Wang X, Chen H, Song L, Ye L, Wang SH et al (2008) Methamphetamine enhances HIV infection of macrophages. Am J Pathol 172(6):1617-1624. doi:10.2353/ajpath.2008.070971 (Pubitemid 351793354)
15. Lundstrom K, Turpin MP (1996) Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 225(3):1068-1072. doi:10.1006/bbrc.1996.1296 (Pubitemid 26319228)
16. Marcondes MC, Flynn C, Watry DD, Zandonatti M, Fox HS (2010) Methamphetamine increases brain viral load and activates natural killer cells in simian immunodeficiency virus-infected monkeys. Am J Pathol 177(1):355-361. doi:10.2353/ajpath.2010.090953
17. Marquez C, Mitchell SJ, Hare CB, John M, Klausner JD (2009) Methamphetamine use, sexual activity, patient-provider communication, and medication adherence among HIV-infected patients in care, San Francisco 2004-2006. AIDS Care 21(5):575-582. doi:10.1080/09540120802385579
18. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M et al (1997) Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol 42(6):963-972. doi:10.1002/ana.410420618 (Pubitemid 28008427)
19. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA et al (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372(9651):1733-1745. doi:10.1016/S0140-6736 (08) 61311-2
20. McKenna F, McLaughlin PJ, Lewis BJ, Sibbring GC, Cummerson JA, Bowen-Jones D et al (2002) Dopamine receptor expression on human T-and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol 132(1-2):34-40. doi:S0165572802002801 (Pubitemid 35333323)
21. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78(1):189-225 (Pubitemid 28070979)
22. Nath A (2010) Human immunodeficiency virus-associated neurocognitive disorder: pathophysiology in relation to drug addiction. Ann NY Acad Sci 1187:122-128. doi:10.1111/j.1749-6632.2009.05277.x
23. Nath A, Maragos WF, Avison MJ, Schmitt FA, Berger JR (2001) Acceleration of HIV dementia with methamphetamine and cocaine. J Neurovirol 7(1):66-71 (Pubitemid 32904361)
24. Reiner BC, Keblesh JP, Xiong H (2009) Methamphetamine abuse, HIV infection, and neurotoxicity. Int J Physiol Pathophysiol Pharmacol 1(2):162-179
25. Rippeth JD, Heaton RK, Carey CL, Marcotte TD, Moore DJ, Gonzalez R et al (2004) Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 10(1):1-14. doi:10.1017/S1355617704101021 (Pubitemid 38128457)
26. Sasieni P (1997) From genotypes to genes: doubling the sample size. Biometrics 53:1253-1261 (Pubitemid 28013569)
27. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, Grant I (2007) Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 17:275-297 (Pubitemid 47498174)
28. Strathdee SA, Stockman JK (2010) Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Curr HIV AIDS Rep 7(2):99-106. doi:10.1007/s11904-010-0043-7
29. Tozzi V, Balestra P, Lorenzini P, Bellagamba R, Galgani S, Corpolongo A, Narciso P (2005) Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol 11:265-73. doi:10.1080/13550280590952790 (Pubitemid 41122414)
30. Valcour VG, Yee P, Williams AE, Shiramizu B, Watters M, Selnes O, Paul R, Shikuma C, Sacktor N (2006) Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection-The Hawaii Aging with HIV Cohort. J Neurovirol 12:387-91. doi:10.1080/13550280600915339 (Pubitemid 44650051)
31. Valcour VG, Shiramizu BT, Shikuma CM (2010) HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications. J Leukoc Biol 87:621-626